产品
Reagent and Library Prep Kit Bundles Available for the MiniSeq System

Order your MiniSeq reagents and library prep kits together for additional savings and convenience. Select item 20005610 and add to your cart.

TruSight Tumor 15

这款靶向测序panel可在单次检测中以简便快速的工作流程评估实体瘤中的15个常见突变基因。 Read More...
选择产品

TruSight Tumor 15 MiSeq Kit

OP-101-1001

TruSight Tumor 15 (Library Prep Only)

OP-101-1002

TruSight Tumor 15 MiniSeq Kit

20005610

TruSight Tumor 15

Product Highlights

TruSight肿瘤15使用下一代测序(NGS)技术，对实体肿瘤中常见的15个基因进行全面评估。它能准确检测20ng起始DNA的低频变异，并对福尔马林固定、石蜡包埋(FFPE)的肿瘤组织进行了优化。

查看基因列表

具有快速的工作流程，可以很容易地集成到实验室程序中，该面板提供了一个准确、经济、快速的实体肿瘤分析的单一分析方法。

TruSight肿瘤面板提供:

  • 全面的工作流程:用一个简单的工作流程来评估15个基因，而不是用聚合酶链反应(PCR)进行单一、迭代的基因检测
  • 高效：快速周转，只需 3.5 小时的动手时间，从 DNA 到数据大约需要 36 小时
  • 实体肿瘤相关基因含量:从相关行业指南中选择体细胞变异1, 关键意见领袖2,3, 和制药研究
  • 低DNA输入的敏感变异检测:使用来自FFPE组织样本的20 ng DNA，精确检测5%等位基因频率的体细胞变异
TruSight肿瘤15样本数据集

使用TruSight Tumor 15制备3份人类参考样本和5份从肺、结肠、黑色素瘤和乳腺肿瘤中提取的ffpe DNA样本。这些文库在MiniSeq系统上测序，使用2 × 150 bp读取长度配置双索引的高输出试剂盒。Q30及以上的碱基产量为94.9%，总产量为7.6 g。

浏览BaseSpace Sequence Hub中的数据:

访问此数据需要BaseSpace Sequence Hub登录。
注册 BaseSpace Sequence Hub

查看所有癌症研究小组

Frequently Purchased Together

规格

计划推荐

仪器 推荐的样本数 读长
MiniSeq System Samples per run: mid output: 2-3, high output: 8 (based on 93.5% of the bases covered at 500x minimum) 2 × 150 bp (max recommended)
MiSeq System 8 samples per run with v3 reagents (based on 93.5% of the bases covered at 500x minimum) 2 × 151 bp (max recommended)

Method-Specific Workflow Example

 
Prepare Kit for:
Targeted Gene Sequencing
 
Sequence Efficiently with:
MiniSeq System
MiSeq System
 
Analyze Your Data with:
Local Run Manager Software (TruSight Tumor 15 Module)
VariantStudio Software
 
TruSight Tumor 15 Gene List
AKT1 GNA11 NRAS
BRAF GNAQ PDGFRA
EGFR KIT PIK3CA
ERBB2 KRAS RET
FOXL2 MET TP53

产品资料

Analysis of Cell-Free DNA with the TruSight Tumor 15 Assay

White Paper | PDF < 1 MB

Assessing the Quality of FFPE Samples for Preparation of TruSight® Tumor 15 Sequencing Libraries

White Paper | PDF < 1 MB

Analysis of TP53 Variants in Bone Marrow Aspirates With TruSight Tumor 15

White Paper | PDF < 1 MB

TruSight Tumor 15

Data Sheet | PDF < 1 MB

Illumina VariantStudio Data Analysis Software

Data Sheet | PDF 2 MB

Multi-site analytical validation of TruSight® Tumor 15 (TST15), determining robustness and concordance.

Technical Note | PDF < 1 MB

TruSight Tumor 15 Data Analysis

Technical Note | PDF < 1 MB

手册和支持信息

TruSight Tumor 15 Reference Guide Documentation

TruSight Tumor 15 Checklist Documentation

MiSeq Reporter TruSight Tumor 15 Workflow Guide Documentation

Illumina Experiment Manager User Guide Documentation

TruSight Tumor 15 Consumables and Equipment Documentation

TruSight Tumor 15 Support Documentation

自定义协议选择器
Generates customized, end-to-end instructions

全部 TruSight Tumor 15  Support  

Kit requires MiSeq Software v2.6 or higher and the Illumina Annotation Engine. Download files

Related Products

相关解决方案

References
  1. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii1-9.
  2. Rousseau B, Jacquot C, Le Palabe J, et al. TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in non-small cell lung cancer treatment. Sci Rep. 2015;5:10356.
  3. Haley L, Tseng LH, Zheng G, et al. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers [published online July 31 2015]. Mod Pathol. 2015. doi: 10.1038/modpathol.2015.86.
Back to Top  
仅供研究使用。不得用于诊断。

创新技术

在Illumina，我们的目标是应用创新技术来分析遗传变异和功能，实现几年前甚至还无法想象的研究。我们的任务是提供创新、灵活、可扩展的解决方案以满足客户的需求。作为一家重视合作互动、快速交付解决方案和提供高质量水平的全球性公司，我们努力应对这一挑战。Illumina创新的测序和芯片技术正在推动生命科学研究、转化和消费者基因组学以及分子诊断中的进展。

所有商标均为 Illumina 公司或其各自所有者的财产。
具体商标信息，请参见 www.illumina.com.cn/company/legal.html.

© 2022 Illumina, Inc. All rights reserved.